Restricted accessLetterFirst published online 2025-3
Challenges and implications of anti-JCV antibody serology variability among different assays in natalizumab treatment: A call for standardization and transparency in clinical practice
PolmanCHO’ConnorPWHavrdovaE, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med2006; 354(9): 899–910.
2.
TanCSKoralnikIJ. Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: Clinical features and pathogenesis. Lancet Neurol2010; 9(4): 425–437.
3.
MillsEAMao-DraayerY. Understanding progressive multifocal leukoencephalopathy risk in multiple sclerosis patients treated with immunomodulatory therapies: A bird’s eye view. Front Immunol2018; 9: 138.
4.
OlssonTAchironAAlfredssonL, et al. Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort. Mult Scler J2013; 19(11): 1533–1538.
5.
VukusicSRollotFCaseyR, et al. Progressive multifocal leukoencephalopathy incidence and risk stratification among natalizumab users in France. JAMA Neurol2020; 77(1): 94–102.
6.
HemmerBWiendlHRothK, et al. Efficacy and safety of proposed biosimilar natalizumab (PB006) in patients with relapsing-remitting multiple sclerosis. JAMA Neurol2023; 80(3): 298–307.
7.
TobosoITejeda-VelardeAAlvarez-LafuenteR, et al. New algorithms improving PML risk stratification in MS patients treated with natalizumab. Front Neurol2020; 11: 579438.
8.
JørgensenJTHersomM. Companion diagnostics: A tool to improve pharmacotherapy. Ann Transl Med2016; 4(24): 482–482.
